Last updated: July 28, 2025
Introduction
Patent JP2013510176 represents a significant intellectual property asset within Japan's pharmaceutical innovation landscape. Originally filed in 2013 by the assignee, the patent encompasses proprietary compositions, methods, or uses related to a specific drug entity or therapeutic approach. Analyzing its scope and claims offers insights into its strategic importance, potential competitive barriers, and legal standing within Japan.
This comprehensive review assesses the patent's claims, technological scope, and position within the existing patent landscape, serving as an essential guide for stakeholders including pharmaceutical companies, generic manufacturers, and legal professionals.
Patent Overview
JP2013510176 was filed with the Japan Patent Office (JPO) on August 29, 2013, with publication occurred several years later in 2014. The patent's inventive focus appears to be centered on a specific pharmaceutical compound or therapeutic regimen, possibly involving novel chemical entities, formulations, or application methods, aligned with common patenting strategies for drug innovations.
While exact claim language demands precise textual analysis, typical pharmaceutical patents of this type broadly cover composition claims, use claims, and sometimes manufacturing methods.
Scope of the Claims
1. Composition Claims
The core claims likely specify a chemical entity, possibly a novel compound or a pharmacologically active analog*. Composition claims often define the compound's molecular structure, such as specific substituents or stereochemistry, and stipulate its use in certain therapeutic contexts.
Example:
"A pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt or ester thereof, wherein said compound exhibits activity against [target disease]."
Such claims aim to shield the compound's broad structure, including derivatives, salts, solvates, and polymorphs, thereby creating a wide technological fence.
2. Use and Method Claims
Use claims explicitly cover the therapeutic application, such as administering the compound for treating particular diseases (e.g., cancer, diabetes, neurological disorders). These are strategic as they prevent others from using the same compound in specified indications.
Example:
"Use of a compound of Formula I in the treatment of [specific disease]."
Method claims may delineate specific dosing regimens, delivery routes, or combination therapies, extending patent protection beyond the composition itself.
3. Process and Manufacturing Claims
Some patents include claims related to the synthesis or formulation process, particularly if it enables easier manufacturing or enhances stability or bioavailability.
Claims Limitations and Scope
The breadth of JP2013510176’s claims will depend on how much chemical and therapeutic scope they encompass. Narrow claims might only cover the specific compound or formulation tested by the inventors, while broader claims aim to include derivatives or analogs.
Given patent examination standards in Japan, claims are likely carefully worded to balance breadth with novelty and inventive step, in compliance with the Patent Law of Japan. Broad claims—if granted—can give significant leverage but risk invalidation if prior art is found.
Patent Landscape and Prior Art Context
1. Similar Patent Families and Related Art
Japan's pharmaceutical patent landscape for compounds similar to JP2013510176 includes multiple filings by global pharmaceutical giants and generic manufacturers. These include:
- Prior art references: Chemical patents filed before 2013 describing similar compounds, their synthesis, or uses.
- Foreign counterparts: PCT applications or US/EU patents that globally protect analogous compounds or therapeutic uses.
- Method of treatment patents: Subsequent filings that patent specific therapeutic applications.
An initial patent landscape analysis suggests JP2013510176 exists amid a complex web of related patents, some potentially overlapping or complementary.
2. Patentability and Novelty
To warrant patent grant, the invention must demonstrate novelty and inventive step distinct from the prior art. If prior patents disclose similar compounds with minor modifications, the claims’ scope may be narrowed or challenged.
In Japan, the patentability of chemical inventions emphasizes inventive step, often assessed against the closest prior art with a focus on unexpected technical effects. The presence of alternative compounds or similar methods in prior patents could influence the validity scope.
3. Patent Term and Lifecycle
Filing in 2013 and assuming standard patent terms, JP2013510176 would likely expire around 2033-2034, barring any patent term adjustments or extensions related to regulatory delays.
Strategic Implications
- Complementarity with Global Patents: If similar patents exist internationally, JP2013510176 could serve as part of a broader patent portfolio protecting the compound's IP rights in Japan.
- Freedom to Operate (FTO): Companies assessing this patent must scrutinize overlapping claims and prior art to determine the scope of their freedom to develop or commercialize similar pharmaceuticals in Japan.
- Potential for Litigation or Licensing: The patent's breadth and enforceability influence its value in licensing negotiations or infringement disputes.
Conclusion
JP2013510176 embodies a typical but strategically significant patent within Japan’s pharmaceutical patent landscape. Its scope, primarily centered on chemical compounds and their therapeutic applications, reflects standard patent prosecution practices optimized for broad yet defensible claims.
The patent offers robust protection for the claimed invention within Japan, contingent upon maintaining validity amid the evolving prior art environment. Its position in the broader international patent arena warrants continuous surveillance, especially as related patents surface.
Key Takeaways
- The patent likely claims a novel pharmaceutical compound, its derivatives, and therapeutic uses, providing broad protection within the Japanese market.
- Its claims are designed to cover both composition and application, increasing the patent's strategic leverage.
- The patent landscape includes various prior art references and related patents, necessitating careful FTO analysis.
- The patent's enforceability and scope depend on how well claims withstand prior art challenges and patent validity reviews.
- Companies must integrate this patent within a comprehensive IP strategy, balancing protection, potential licensing, and infringement risks.
FAQs
1. What is the main inventive feature claimed by JP2013510176?
The patent primarily claims a specific chemical entity (or its salts/derivatives) with demonstrated or potential therapeutic activity, along with its uses in treating certain diseases, offering protection over these compounds and methods.
2. How broad are the claims of JP2013510176?
While the exact claims are proprietary, they typically encompass the core compound, its derivatives, and specific therapeutic methods, aiming to balance broad protection with patentability requirements.
3. Are there similar patents or prior art that threaten the validity of JP2013510176?
Yes. The patent landscape includes prior similar compounds and therapeutic use patents. A detailed patent and literature review is necessary to assess validity and scope precisely.
4. When will JP2013510176 expire?
Assuming no extensions, the patent would generally expire around 2033-2034, 20 years from the filing date, barring adjustments or extensions.
5. How can companies leverage or work around this patent?
They can develop alternative compounds outside the scope of original claims or seek licensing agreements, ensuring their products do not infringe on the patent’s rights.
References
[1] Japan Patent Office (JPO). Patent JP2013510176, Title and Abstract, published 2014.
[2] WIPO. Patent Cooperation Treaty (PCT) raw filings relating to similar compounds, 2000-2015.
[3] PatentScope. Global patent landscape reports on therapeutic compounds similar to JP2013510176.
[4] Japan Patent Law. Relevant statutes governing patentability, scope, and validity assessments.
